"So, I'm wondering if Apabetalone can have a profound effect on folks with T2D and recent Acute Coronary Syndrome who are taking SGLT2i, and demonstrate a reduction in eGFR AND HbA1c (similar to, or better than Semaglutide), then maybe Apabetalone has a shot at affecting positive outcomes in an Alzheimers Disease trial too.  Now there's an additional market!!! (as has been pointed out on this board many times before).  However, the Novo Nordisk trial is expected to take a couple of years"

To add even more complexity, there's a good chance that apabetalone and GLP-1 receptor agonists work well together too. Unfortunately, only 96 patients in BETonMACE were on GLP-1RA, compared to 298 on SGLT2i and 359 on the DPP4 inhibitors. About a year ago, Resverlogix press released on the beneficial effects of apabetalone incombo with SGLT2i or DPP4i. However, no mention from the company about apabetalone combo with GLP-1RA. It could be that they just didn't have enough patients on that drug to have the power to see anything. Importantly, the most well understood mechanism of action for DPP4i is to prevent the degradation of GLP-1. DPP4 is a peptidase that rapidly degrades GLP-1 in the circulation. DPP4 inhibitors slow this degradation and prolong the activity of GLP-1.......analagous to use of GLP-1R agonists. Same effect......increase amount of circulating ligand to bind to GLP-1 receptors! 

BDAZ